Combination therapyFDA-approvedFirst-line

Nivolumab + Ipilimumab

How it works

Combination of nivolumab, which blocks PD-1, and ipilimumab, which blocks CTLA-4, to enhance the immune system's ability to attack cancer cells.

Cancer types

Melanoma— All patients

Efficacy

Studies show that around 50% of patients achieve an objective response, with median overall survival of approximately 10 months.

Side effects

Severe

This treatment carries a higher risk of serious side effects. Close medical monitoring is required throughout treatment.

This information is provided for general education only and is not medical advice. Always consult a qualified healthcare professional before making treatment decisions.